PPARG and esophageal squamous cell carcinoma: Another study has reported the reduced expression of PPARγ in esophageal tumor lesions and proved that ESCC cell proliferation could be inhibited by efatutazone, a PPARγ agonist, by inactivating the PI3K–Akt and MAPK pathways [154].